Authors: Delord, Jean-Pierre¹; Bennouna, Jaafar²; Mourey, Loïc¹; Bougaret, Joël³; Brandely-Talbot, Maud⁴; Ferré, Pierre³

Source: Clinical Pharmacokinetics, Volume 51, Number 6, 1 June 2012 , pp. 357-364(8)

Publisher: Adis International

Abstract:

Background Vinflunine is a new-generation microtubule inhibitor, which is currently registered in Europe and in some countries elsewhere as an intravenous formulation for the second-line treatment of transitional urothelial cell carcinoma. On the basis of favourable non-clinical results, the clinical development of an oral formulation was initiated.

Objective The absolute oral bioavailability was investigated in patients through two consecutive trials: the first trial used soft gelatin capsules filled with solubilized vinflunine (SLCaps), while the second study investigated hard gelatin capsules containing vinflunine as a formulated powder (HPCaps).

Study Design Each pharmacokinetic trial was conducted according to a randomized cross-over design. Patients received 120 mg/m2 of either oral (SLCaps or HPCaps) or intravenous vinflunine on day 1, followed by the alternate dosing route after a 2-week washout period. Blood samples were collected over 168 hours. A pharmacokinetic analysis was conducted for each patient and route of dosing to derive the absolute oral bioavailability of SLCaps and HPCaps.

Results A total of 12 and 22 patients were enrolled, for SLCaps and HPCaps, respectively. Vinflunine absorption was rapid for both oral formulations. Blood concentrations peaked at 2.5 hours following oral intake with food, and then decreased similarly to the intravenous profile. The mean absolute bioavailability was high, at 58.3 ± 14.4% (SLCaps) and 57.3 ± 11% (HPCaps), with limited inter-individual variability (coefficient of variation = 25% and 19% for SLCaps and HPCaps, respectively). Neither sequence nor period effects were detected. The gastro-intestinal tolerance was satisfactory. The main drug-related adverse events were asthenia, fatigue, constipation and neutropenia, mostly of grade 1 or 2. No grade 4 and no drug-related serious adverse events were reported.

Conclusion The high bioavailability and low inter-individual variability are favourable pharmacokinetic properties, which could be valuable for further clinical development of oral vinflunine.

Keywords: Antineoplastics; Bioavailability; Pharmacokinetics; Pharmacology; Tubulin-inhibitors; Vinflunine

Document Type: Research article

Affiliations: 1: 1 Institut Claudius Regaud, Toulouse, France 2: 2 Centre René Gauducheau, Saint Herblain, France 3: 3 Institut de Recherche Pierre Fabre, Toulouse, France 4: 4 Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France

Publication date: 2012-06-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Delord, Jean-Pierre ;  Bennouna, Jaafar ;  Mourey, Loïc ;  Bougaret, Joël ;  Brandely-Talbot, Maud ;  Ferré, Pierre

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers